Market Access News | pharmaphorum

News

NICE backs funding for MSD's diabetes drug Steglatro

NICE has recommended that England’s NHS should routinely fund Merck, Sharpe, and Dohme’s type 2 diabetes drug Steglatro in a final decision, after the company undercut rivals from the same

News

Health secretary hints at 'constructive' talks over CF drugs

Health secretary Matt Hancock has offered hope to thousands of people in the UK who have been denied access to powerful cystic fibrosis drugs because of a row over pricing with manufacturer

News

Sanofi may airlift medicines into UK after Brexit

France’s Sanofi has said it may fly supplies of flu vaccine into the UK if Brexit causes travel disruption after the country leaves the EU.

News

Novo prevents Teva's Victoza rival launch until 2023

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

News

Praluent approved to reduce CV risk in Europe

The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD), giving the drug another advan

News

Illustration of a nerve cell on a colored background with light effects

Acadia faces US federal probe into Nuplazid marketing

Acadia Pharmaceuticals may have thought it got out of trouble last year after an FDA safety investigation into its flagship Parkinson’s drug Nuplazid revealed no new risks – but documents h

NICE backs funding for MSD's diabetes drug Steglatro

Health secretary hints at 'constructive' talks over CF drugs

Sanofi may airlift medicines into UK after Brexit

Novo prevents Teva's Victoza rival launch until 2023

Praluent approved to reduce CV risk in Europe

Acadia faces US federal probe into Nuplazid marketing

On addressing drug waste and ensuring access, with Jeff Harp...

How to meet your physicians where they are online

News

Editor's Picks